CME Revenue Growth (YoY) Analysis

CME's current Revenue Growth (YoY) of 0.8% means that its sales in the most recent trailing twelve months were only 0.8% higher than the same period a year ago – a measure of how fast the company is expanding its top line.

This places CME well below its sector, where the median revenue growth is 8.0%, and puts it at the 13th percentile among peers, indicating that the vast majority of comparable companies are growing faster. The year-over-year change is not reported (N/A), but the quarter-over-quarter change shows a massive decline of -94.5%, and the two most recent historical values reveal a drop from 14.5% to 0.8%, pointing to a sharp deceleration in revenue. The combination of a very low growth rate and a rapidly deteriorating trend raises the risk that CME’s revenue may continue to stall or contract, creating a headwind for the stock. This metric contradicts the overall NEUTRAL verdict on CME, as the growth slowdown and weak peer comparison suggest downside pressure that a neutral rating would not typically reflect.

Frequently Asked Questions

Closest Sector Peers